.
it, confers susceptibility to panic disorder. Replication studies in independent samples with nuclear families
Our results thus failed to provide evidence for an panic disorder. However, they suggest that allelic variAbnormalities of adenosinergic neuromodulation ation at the adenosine A 2a AR gene may contribute to have been associated with panic disorder. The adenosthe development of the disease. ine receptor (AR) antagonist caffeine induces panic Positive association findings have to be interpreted attacks in patients with the disorder 1 and caffeine with caution. It has been stressed that the candidate intoxication (DSM-III-R) 2 resembles anxiety disorders. gene approach in association studies as applied in this Adenosine analogues have depressant effects on respirstudy will provide for numerous false positive results atory function in the brainstem, 3 an impairment of by chance with the commonly accepted significance level of P Ͻ 0.05 given the numerous possible candidepressant brainstem respiratory mechanisms being 
The numbering of A 1 AR exon 5 and 6 nucleotides is according to Ren and Stiles 20 and of A 2a AR exon 1 and 2 nucleotides according to Le et al. 21 Intron nucleotides were numbered − or + depending on their 5′-or 3′-localization in relation to the exon as the complete sequence of the introns has not yet been established. date genes.
12 Also, artifacts such as population stratifi-100%, 15 the presence of such a coding variant cannot be completely excluded. An alternative possibility is cation effects can easily lead to false positive findings in case-control association studies. 13 Replication, that a functional variant resides in a regulatory region of the A 2a AR gene leading to altered levels of receptor therefore is necessary and should be attempted with family-based linkage studies using the transmission expression. In fact, mice lacking the A 2a AR were recently shown to be markedly more anxious than disequilibrium test. 14 The 1083C/T polymorphism of the A 2a AR gene does wild-type mice. 16 The regulatory regions of the human A 2a AR gene have yet to be defined at the molecular not change the amino acid sequence of the protein.
Most likely, the 1083C/T polymorphism is not level. 17 A systematic mutation screening of these regions will therefore be a matter of future studies. involved directly in the etiology of panic disorder but is in linkage disequilibrium with the true functional
In conclusion, the observed association between a silent polymorphism in the coding region of the A 2a AR variant either within the A 2a AR gene itself or within an adjacent gene. In the present study we found no evigene and panic disorder is suggestive for an involvement of the A 2a AR in the pathogenesis of panic disdence for a functional variant in the coding region of the A 2a AR gene. As the sensitivity of SSCA is not order. If the finding can be independently replicated, future studies will aim on the identification of the true functional variant in the A 2a AR gene.
Methods

Subjects
The mutation screening sample consisted of 38 patients with panic disorder. The association sample included an additional 51 patients. Eighty-nine anonymous blood donors, who were matched according to age, sex and ethnicity, served as controls. The patients were recruited consecutively from in-and outpatient facilities. Lifetime 'best estimate' diagnoses (DSM-III-R) 2 were assessed by an experienced psychiatrist based on multiple sources of information, including personal structured interviews [1. CIDI 18 or 2. SADS-LA 19 ], family history reports and medical records. The inclusion criterion was panic disorder with or without agoraphobia: (a) occurring primary to other major psychiatric disorders (exclusion: simple and social phobia); and (b) representing the predominant syndrome during lifetime. Patients with organic mental or psychotic disorders were excluded.
All probands were unrelated and of German origin. After complete description of the study to the patients, written informed consent was obtained. gene. 20, 21 PCR was carried out in a 25-l total volume, containing 80 ng genomic DNA, 10 pmol of each primer, 200 M dNTPs, 1 U Taq polymerase (Life Technologies, Eggenstein, Germany), 50 mM KCl, 1.5 mM MgCl 2 , 0.01% gelatine, and 10 mM TRIS-HCl Mutagenic primer to abolish a constant restriction site (nucleotide substitution is underlined). b Mutagenic primer to introduce a polymorphic restriction site (nucleotide substitution is underlined). 18 h under two conditions (6 V cm −1 at room tempera-
